Editorial commentary: Polymyxin-resistant Acinetobacter baumannii: urgent action needed.
作者信息
Pogue Jason M, Cohen David A, Marchaim Dror
机构信息
Department of Pharmacy Services, Sinai-Grace Hospital, Detroit Medical Center, Wayne State University School of Medicine, Michigan.
Unit of Infectious Diseases, Assaf Harofeh Medical Center, Zerifin.
出版信息
Clin Infect Dis. 2015 May 1;60(9):1304-7. doi: 10.1093/cid/civ044. Epub 2015 Jan 28.
Abstract
摘要
相似文献
1
Editorial commentary: Polymyxin-resistant Acinetobacter baumannii: urgent action needed.编辑评论：耐多粘菌素鲍曼不动杆菌：亟需采取紧急行动。
Clin Infect Dis. 2015 May 1;60(9):1304-7. doi: 10.1093/cid/civ044. Epub 2015 Jan 28.
2
Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance.耐黏菌素鲍曼不动杆菌：超越碳青霉烯类耐药性
Clin Infect Dis. 2015 May 1;60(9):1295-303. doi: 10.1093/cid/civ048. Epub 2015 Jan 28.
3
Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity.耐多粘菌素、耐碳青霉烯类鲍曼不动杆菌可被三种单独无活性的药物联合使用所根除。
J Antimicrob Chemother. 2017 May 1;72(5):1415-1420. doi: 10.1093/jac/dkx002.
4
Antibacterial activity of carbapenem-based combinations againts multidrug-resistant Acinetobacter baumannii.基于碳青霉烯类的联合用药对多重耐药鲍曼不动杆菌的抗菌活性
J Med Assoc Thai. 2010 Feb;93(2):161-71.
5
Evaluation of the Colistin-Carbapenem Combination in Clinical Isolates of Using the Checkerboard, Etest, and Time-Kill Curve Techniques.运用棋盘法、Etest法和时间杀菌曲线技术评估黏菌素-碳青霉烯类联合用药对[具体临床分离株]的效果
Front Cell Infect Microbiol. 2017 May 24;7:209. doi: 10.3389/fcimb.2017.00209. eCollection 2017.
6
In Vitro Interactions of Antibiotic Combinations of Colistin, Tigecycline, and Doripenem Against Extensively Drug-Resistant and Multidrug-Resistant Acinetobacter baumannii.黏菌素、替加环素和多尼培南抗生素组合对广泛耐药和多重耐药鲍曼不动杆菌的体外相互作用
Ann Lab Med. 2016 Mar;36(2):124-30. doi: 10.3343/alm.2016.36.2.124.
7
In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.黏菌素与替加环素或β-内酰胺类抗生素/β-内酰胺酶抑制剂组合对耐碳青霉烯类鲍曼不动杆菌的体外协同活性。
J Int Med Res. 2013 Dec;41(6):1830-7. doi: 10.1177/0300060513496172.
8
Rapid dissemination of colistin and carbapenem resistant Acinetobacter baumannii in Central Greece: mechanisms of resistance, molecular identification and epidemiological data.希腊中部耐黏菌素和碳青霉烯类鲍曼不动杆菌的快速传播：耐药机制、分子鉴定及流行病学数据
BMC Infect Dis. 2015 Dec 9;15:559. doi: 10.1186/s12879-015-1297-x.
9
In Vitro Bactericidal Activity of Trimethoprim-Sulfamethoxazole Alone and in Combination with Colistin against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates.甲氧苄啶-磺胺甲恶唑单独及与黏菌素联合对耐碳青霉烯鲍曼不动杆菌临床分离株的体外杀菌活性
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6903-6906. doi: 10.1128/AAC.01082-16. Print 2016 Nov.
10
The role of vancomycin in addition with colistin and meropenem against colistin-sensitive multidrug resistant Acinetobacter baumannii causing severe infections in a Paediatric Intensive Care Unit.万古霉素联合黏菌素和美罗培南对在儿科重症监护病房引起严重感染的黏菌素敏感的多重耐药鲍曼不动杆菌的作用。
BMC Infect Dis. 2015 Sep 30;15:393. doi: 10.1186/s12879-015-1133-3.
引用本文的文献
1
Exploring Aspartate Transcarbamoylase: A Promising Broad-Spectrum Target for Drug Development.探索天冬氨酸转氨甲酰酶：药物开发中一个有前景的广谱靶点。
Chembiochem. 2025 Apr 1;26(7):e202401009. doi: 10.1002/cbic.202401009. Epub 2025 Mar 27.
2
Colistin resistance in carbapenem non-susceptible Acinetobacter baumanii in a tertiary care hospital in India: clinical characteristics, antibiotic susceptibility and molecular characterization.印度一家三级护理医院中对碳青霉烯类药物不敏感的鲍曼不动杆菌的多粘菌素耐药性：临床特征、抗生素敏感性和分子特征。
Mol Biol Rep. 2024 Feb 24;51(1):357. doi: 10.1007/s11033-023-08982-5.
3
Comparative metabolomics reveals key pathways associated with the synergistic activity of polymyxin B and rifampicin combination against multidrug-resistant Acinetobacter baumannii.比较代谢组学揭示了多黏菌素 B 和利福平联合用药对多重耐药鲍曼不动杆菌协同作用相关的关键途径。
Biochem Pharmacol. 2021 Feb;184:114400. doi: 10.1016/j.bcp.2020.114400. Epub 2020 Dec 30.
4
A Diverse Panel of Clinical Acinetobacter baumannii for Research and Development.用于研究和开发的临床鲍曼不动杆菌多样化小组。
Antimicrob Agents Chemother. 2020 Sep 21;64(10). doi: 10.1128/AAC.00840-20.
5
Colistin-Resistant Bacteremia: A Serious Threat for Critically Ill Patients.耐黏菌素菌血症：对重症患者的严重威胁。
Microorganisms. 2020 Feb 20;8(2):287. doi: 10.3390/microorganisms8020287.
6
Unlocking NuriPep 1653 From Common Pea Protein: A Potent Antimicrobial Peptide to Tackle a Pan-Drug Resistant .从普通豌豆蛋白中解锁NuriPep 1653：一种对抗泛耐药性的强效抗菌肽
Front Microbiol. 2019 Sep 18;10:2086. doi: 10.3389/fmicb.2019.02086. eCollection 2019.
7
[New antibiotics for severe infections due to multidrug-resistant pathogens : Definitive treatment and escalation].用于多重耐药病原体所致严重感染的新型抗生素：确定性治疗与升级治疗
Anaesthesist. 2019 Nov;68(11):785-800. doi: 10.1007/s00101-019-00646-z.
8
Dissecting Colistin Resistance Mechanisms in Extensively Drug-Resistant Acinetobacter baumannii Clinical Isolates.解析广泛耐药鲍曼不动杆菌临床分离株中多粘菌素耐药机制。
mBio. 2019 Jul 16;10(4):e01083-19. doi: 10.1128/mBio.01083-19.
9
spp. as nosocomial pathogens: Epidemiology and resistance features.作为医院病原体的物种：流行病学和耐药特征
Saudi J Biol Sci. 2018 Mar;25(3):586-596. doi: 10.1016/j.sjbs.2016.02.009. Epub 2016 Feb 11.
10
spp. Infections in Malaysia: A Review of Antimicrobial Resistance Trends, Mechanisms and Epidemiology.马来西亚的物种感染：抗菌药物耐药性趋势、机制及流行病学综述
Front Microbiol. 2017 Dec 12;8:2479. doi: 10.3389/fmicb.2017.02479. eCollection 2017.
本文引用的文献
1
Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance.耐黏菌素鲍曼不动杆菌：超越碳青霉烯类耐药性
Clin Infect Dis. 2015 May 1;60(9):1295-303. doi: 10.1093/cid/civ048. Epub 2015 Jan 28.
2
A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections.静脉注射米诺环素治疗多重耐药鲍曼不动杆菌感染的研究综述。
Clin Infect Dis. 2014 Dec 1;59 Suppl 6:S374-80. doi: 10.1093/cid/ciu613.
3
Acinetobacter sp. isolates from emergency departments in two hospitals of South Korea.从韩国两家医院急诊科分离出的不动杆菌属菌株。
J Med Microbiol. 2014 Oct;63(Pt 10):1363-1368. doi: 10.1099/jmm.0.075325-0. Epub 2014 Jul 25.
4
Spread of a carbapenem- and colistin-resistant Acinetobacter baumannii ST2 clonal strain causing outbreaks in two Sicilian hospitals.碳青霉烯类和多黏菌素耐药鲍曼不动杆菌 ST2 克隆株的传播导致西西里岛两家医院暴发疫情。
J Hosp Infect. 2014 Apr;86(4):260-6. doi: 10.1016/j.jhin.2014.02.001. Epub 2014 Feb 20.
5
Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women.一项评估静脉注射依拉环素在健康男性和女性中的支气管肺分布的I期开放标签安全性和药代动力学研究。
Antimicrob Agents Chemother. 2014;58(4):2113-8. doi: 10.1128/AAC.02036-13. Epub 2014 Jan 27.
6
New β-lactamase inhibitors: a therapeutic renaissance in an MDR world.新型β-内酰胺酶抑制剂：多药耐药时代的治疗新契机
Antimicrob Agents Chemother. 2014;58(4):1835-46. doi: 10.1128/AAC.00826-13. Epub 2013 Dec 30.
7
Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.头孢洛扎他唑巴坦：一种新型头孢菌素/β-内酰胺酶抑制剂组合，对多种耐药性革兰氏阴性杆菌具有活性。
Drugs. 2014 Jan;74(1):31-51. doi: 10.1007/s40265-013-0168-2.
8
Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens.依拉环素（TP-434）的抗菌活性，一种新型氟环素，针对医院和社区病原体。
Antimicrob Agents Chemother. 2013 Nov;57(11):5548-58. doi: 10.1128/AAC.01288-13. Epub 2013 Aug 26.
9
Impaired virulence and fitness of a colistin-resistant clinical isolate of Acinetobacter baumannii in a rat model of pneumonia.在肺炎大鼠模型中，耐多粘菌素的鲍曼不动杆菌临床分离株的毒力和适应性受损。
Antimicrob Agents Chemother. 2013 Oct;57(10):5120-1. doi: 10.1128/AAC.00700-13. Epub 2013 Jul 8.
10
Colistin resistance in a clinical Acinetobacter baumannii strain appearing after colistin treatment: effect on virulence and bacterial fitness.多黏菌素耐药的临床鲍曼不动杆菌菌株出现在多黏菌素治疗后：对毒力和细菌适应性的影响。
Antimicrob Agents Chemother. 2013 Sep;57(9):4587-9. doi: 10.1128/AAC.00543-13. Epub 2013 Jul 8.
Zotero 插件